

Clarke, Modet & C^o
COLOMBIA

SEÑORES
DIVISIÓN DE NUEVAS CREACIONES
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
E. S. D.

COD: 008

RE.: SOLICITUD DE PATENTE EN COLOMBIA
EXPEDIENTE N° 03058786
TITULO: FORMULACIONES TÓPICAS DE BRIVUDINA
ESTABILIZADAS
SOLICITANTE: BERLIN-CHEMIE AG, MENARINI RICERCHE
S.P.A
FECHA SOLICITUD: JULIO 11 DE 2003

ASUNTO: CONTESTACIÓN A REQUERIMIENTO OFICIAL

DILIA RODRIGUEZ D'ALEMAN, en mi condición de apoderada de la sociedad solicitante, por el presente escrito doy respuesta a su auto notificado por estado de 23 de marzo de 2007, el cual vence el día 22 de junio de 2007, y adjunto copia del documento:

- DESAI D.S. ET AL. "Photo-Stabilization of the Tablets of antiviral Drugs SQ32756BV – Arau and Nifedipine by Incorporation of Syntetic Iron Oxides." AAPS (American Association of Pharmaceutical Scientists) Sixth Annual Meeting and Exposition, Washington, D.C., USA. November 17-21, 1991. Pharm Res (N.Y). (1991) 8 (10 Suppl), S176. XP001080067.

Solicitado por esa Superintendencia en virtud del artículo 46 de la Decisión 486 de la Comisión de la Comunidad Andina.

Se proporciona la publicación completa, con lo cual, ese Despacho pueda proceder a realizar el análisis de la patentabilidad de la invención correspondiente a la presente solicitud.



Por lo tanto, se solicita respetuosamente a la Oficina de Patentes Colombiana continuar con el estudio de la solicitud en curso.

Agradezco continuar con el presente trámite.

Señor Jefe,



DILIA RODRIGUEZ D'ALEMAN
ADP/MRO/srdh
P-496



Anexo: Copia del artículo solicitando.

126

XP-001080067

P.D.	1991
P.	SF76
	1

Photo-stabilization of the tablets of antiviral drug SQ32756 (BV-araU) and nifedipine by incorporation of synthetic iron oxides. D. S. Desai, M. A. Abdelhasser, B. A. Rubitski, and S. A. Varla, Bristol-Myers Squibb Co., New Brunswick, New Jersey.

The synthetic iron oxides are known to provide light protection to light sensitive drugs because they are strong absorbers of radiation wavelengths below 400 nm, and because they have great hiding power due to their high refractive indices and high tinctorial capacity. These properties of iron oxides were utilized in photo-stabilization of two light sensitive drugs, the antiviral SQ32756 (BV-araU) and nifedipine. Light stability studies on 10 mg potency aqueous wet granulated core tablets of SQ32756 or nifedipine formulated with either 0.2% w/w yellow iron oxide or without iron oxide were performed by exposing them directly to room light and/or 400 foot candle light. Subsequent to exposure, they were assayed for loss in potencies and increase in levels of degradation. Core tablets containing 0.2% w/w yellow iron oxide were found to be more light stable than those without it. Using core tablets of SQ32756, the photo-stabilization effect of 0.2% w/w yellow iron oxide was also compared with other traditional light protection measures such as coating. Inclusion of 0.2% w/w yellow, red, or black iron oxide into the core tablets gave them more light protection than even an aqueous Opadry® white film coat up to 11% w/w of core tablet weight. Furthermore, inclusion of 0.05% w/w red and 0.04% w/w yellow iron oxides into core tablets gave them more light protection than the inclusion of either 0.2% w/w yellow or red iron oxide.

03-58786

127
26
0452

INTERNATIONAL SEARCH REPORT

Inter-
nal Application No
PCT/EP 02/00163

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/70 A61K47/02 A61P31/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, INSPEC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DESAI D S ET AL: "PHOTO - STABILIZATION OF THE TABLETS OF ANTIVIRAL DRUG SQ32756 BY - ARAU AND NIFEDIPINE BY INCORPORATION OF SYNTHETIC IRON OXIDES." AAPS (AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS) SIXTH ANNUAL MEETING AND EXPOSITION, WASHINGTON, D.C., USA, NOVEMBER 17-21, 1991. PHARM RES (N Y). (1991) 8 (10 SUPPL), S176. , XP001080067 abstract	1-13
Y	DE 41 22 337 A (CEDONA PHARM BV) 14 January 1993 (1993-01-14) column 1, line 17-23; claims 1-3 -/-	1-13

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the International filing date

L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document relating to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

21 June 2002

Date of mailing of the international search report

08/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5518 Patentkan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Luangkhot, N

INTERNATIONAL SEARCH REPORT

Inventor's Application No
PCT/EP 02/00163

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 072 137 A (BEECHAM GROUP PLC) 16 February 1983 (1983-02-16) page 1, paragraph 3; claims 1,2 page 4, paragraph 2	1-13
A	GB 2 306 324 A (KAPPA PHARMACEUTICALS LTD) 7 May 1997 (1997-05-07) page 1, paragraph 4; claims 1-6	1-13
A	EP 1 064 946 A (GODFREY HELEN REBECCA) 3 January 2001 (2001-01-03) claims 1,8,10	1-13

EXAMEN TÉCNICO DE FONDO			
Nº Radicación	03-58786	Fecha de presentación	10.03.03
Nº Radicación	EP 1100968	Fecha de Prioridad	12.01.01
Palabras clave			
TRIVIRIDINA			
GLOBO			

CLASIFICACIONES INTERNACIONALES DE BUSQUEDA			
A61K 49/00			

DOCUMENTOS CORRESPONDIENTES EN OTROS PAISES			
NO 0756913			
Patente Original			

BASES DE DATOS CONSULTADAS			

INFORMES DE EXAMENES EN OTRAS OFICINAS		
Oficina	Fecha	Rev. afectadas

ANTERIORIDADES ENCONTRADAS		
Documento	Relevancia	Rev. afectadas
DC 417233		
EP 032133		

LITERATURA NO PATENTES		
Documento	Relevancia	Rev. afectadas

Observaciones
Art 46.

Fecha de examen
15.03.07